1 pplied glutamate or NMDA was not affected by serotonin agonists.

2 e designed and prepared as potential 5-HT(6) serotonin agonists.

3 derivative DOI (2) are commonly used 5-HT(2) serotonin agonists.

4 ctivity as monoamine-releasing agents and as serotonin agonists.

5                                          The serotonin agonist 8-hydroxy-di-propylaminotetralin (8-OH

6   m-Chlorophenylpiperazine (mCPP) is a mixed serotonin agonist/antagonist used extensively in psychia

7  before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (T

8 e administration of quipazine (0.5 mg/kg), a serotonin agonist, for a period of 6 weeks.

9                                          The serotonin agonist had no effect on UA mechanics in a gro

10 amine (5-CT, 100 nM, i.e., 6.39 pg), another serotonin agonist, into the dorsal raphe and (2) 5-HT7 r

11 a U.S. Food and Drug Administration-approved serotonin agonist (lorcaserin) to septic rats greatly im

12 he firing of 5-HT neurons contributes to the serotonin agonist-mediated inhibition of morphine-induce

13 t treatment with robotic step training and a serotonin agonist, quipazine, generated significant reco

14 r 7 on intrinsic hypoglossal activity and on serotonin agonist (serotonin, 5-carboxamidotryptamine ma

15 , such as carcinoid syndrome, and the use of serotonin agonists, such as fenfluoramine have been asso

16 of sensitivity of the circadian pacemaker to serotonin agonists, the present study used quantitative

17                    Additionally, repurposing serotonin agonists to inhibit CpxA may represent a poten

18 timulation of either nucleus by electrode or serotonin agonist yields equivalent effects on circadian